Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma

Published:2023-10-04 Issue:1 Volume:103 Page:199-209
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Forberg Aidan L.,Unrau Jordan,Weber Kennedee S.,Rutz Alison C.,Lund Shelby,Guidinger Jinda,Pelzel Andrew,Hauge Jackson,Hemmen Ainslee J.,Hartert Keenan T.^ORCID

Funder

Minnesota State University, Mankato

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05478-x.pdf

Reference65 articles.

1. Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73. https://doi.org/10.3322/caac.21763

2. Sehn LH, Salles G (2021) Diffuse Large B-Cell Lymphoma 384:842–858. https://doi.org/10.1056/NEJMra2027612.Diffuse

3. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006. https://doi.org/10.1056/NEJM199304083281404

4. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386. https://doi.org/10.1056/nejmoa2115304

5. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130:1800–1808. https://doi.org/10.1182/blood-2017-03-769620

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural killer cell-associated prognosis model characterizes immune landscape and treatment efficacy of diffuse large B cell lymphoma;Cytokine;2024-10

2. Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets;American Journal of Cancer Research;2024